Rice Hall James & Associates LLC Acquires New Position in Establishment Labs Holdings Inc. $ESTA

Rice Hall James & Associates LLC acquired a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 560,935 shares of the company’s stock, valued at approximately $48,134,000. Establishment Labs comprises about 2.3% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 5th biggest holding.

Several other institutional investors have also added to or reduced their stakes in the business. KBC Group NV bought a new stake in shares of Establishment Labs in the first quarter valued at approximately $28,000. Kestra Advisory Services LLC bought a new position in Establishment Labs in the 4th quarter worth approximately $47,000. Quarry LP purchased a new position in Establishment Labs in the 3rd quarter valued at approximately $34,000. State of Wyoming purchased a new position in Establishment Labs in the 2nd quarter valued at approximately $87,000. Finally, MV Capital Management Inc. bought a new stake in Establishment Labs during the 4th quarter valued at $146,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ESTA. Citigroup raised Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a report on Thursday. BTIG Research raised their target price on Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Mizuho upped their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.25.

Establishment Labs Stock Down 3.6%

ESTA opened at $76.62 on Tuesday. The firm has a market capitalization of $2.28 billion, a P/E ratio of -58.49 and a beta of 1.07. Establishment Labs Holdings Inc. has a one year low of $36.53 and a one year high of $97.59. The company has a fifty day moving average price of $86.83 and a 200-day moving average price of $74.73. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The business had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company’s quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.57) EPS. Equities research analysts expect that Establishment Labs Holdings Inc. will post -1.16 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.